- Home
- HWH vs JAGX Comparison
HWH vs JAGX Comparison
Compare HWH & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWH
- JAGX
- Stock Information
- Founded
- HWH 2021
- JAGX 2013
- Country
- HWH United States
- JAGX United States
- Employees
- HWH N/A
- JAGX N/A
- Industry
- HWH Other Pharmaceuticals
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- HWH Health Care
- JAGX Health Care
- Exchange
- HWH Nasdaq
- JAGX Nasdaq
- Market Cap
- HWH 6.9M
- JAGX 7.4M
- IPO Year
- HWH N/A
- JAGX N/A
- Fundamental
- Price
- HWH $1.49
- JAGX $5.88
- Analyst Decision
- HWH
- JAGX
- Analyst Count
- HWH 0
- JAGX 0
- Target Price
- HWH N/A
- JAGX N/A
- AVG Volume (30 Days)
- HWH 2.7M
- JAGX 247.5K
- Earning Date
- HWH 05-27-2025
- JAGX 05-15-2025
- Dividend Yield
- HWH N/A
- JAGX N/A
- EPS Growth
- HWH N/A
- JAGX N/A
- EPS
- HWH N/A
- JAGX N/A
- Revenue
- HWH $1,253,577.00
- JAGX $11,689,000.00
- Revenue This Year
- HWH N/A
- JAGX $22.41
- Revenue Next Year
- HWH N/A
- JAGX $30.00
- P/E Ratio
- HWH N/A
- JAGX N/A
- Revenue Growth
- HWH 50.94
- JAGX 19.75
- 52 Week Low
- HWH $0.90
- JAGX $4.02
- 52 Week High
- HWH $10.50
- JAGX $502.50
- Technical
- Relative Strength Index (RSI)
- HWH 59.33
- JAGX 37.09
- Support Level
- HWH $1.07
- JAGX $5.30
- Resistance Level
- HWH $2.08
- JAGX $13.20
- Average True Range (ATR)
- HWH 0.17
- JAGX 1.49
- MACD
- HWH 0.06
- JAGX -0.57
- Stochastic Oscillator
- HWH 42.16
- JAGX 7.30
About HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.